Use of herpes vectors for tumor therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9827307
SERIAL NO

13769182

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GEORGETOWN UNIVERSITYWASHINGTON DC 20057

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Martuza, Robert L Marble Head, US 25 358
Rabkin, Samuel D Chevy Chase, US 18 265
Toda, Masahiro Yokohama, JP 38 605

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00